**Author details**

Anush Patel1 \*, Haisam Abid<sup>2</sup> and Amrat Kumar3

1 Hematology/Oncology, Bassett Medical Center, Cooperstown, NY, USA

2 Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

3 Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA

\*Address all correspondence to: anushpatel@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**61**

*The Endocrinological Side Effects of Immunotherapies DOI: http://dx.doi.org/10.5772/intechopen.96491*

inhibitors: a review." JAMA oncology

[9] Weber, Jeffrey S., et al. "Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced

[10] Maher, V. Ellen, et al. "Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody." Journal of Clinical Oncology 37.30

[11] Eggermont, Alexander MM, et al. "Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial." JAMA oncology 6.4 (2020): 519-527.

[12] Lo, Jennifer A., David E. Fisher, and Keith T. Flaherty. "Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy." JAMA oncology 1.9 (2015): 1340-1341.

"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis." J Clin Oncol 33.7 (2015):

[13] Teulings, Hansje-Eva, et al.

[14] Faje, Alexander T., et al.

(2014): 4078-4085.

"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma." The Journal of Clinical Endocrinology & Metabolism 99.11

[15] Faje, Alexander. "Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights." Pituitary 19.1 (2016): 82-92.

773-781.

2.10 (2016): 1346-1353.

melanoma." (2017).

(2019): 2730-2737.

[1] Horvat, Troy Z., et al. "Immunerelated adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." Journal of Clinical Oncology 33.28 (2015): 3193.

[2] Michot, J. M., et al. "Immune-related adverse events with immune checkpoint blockade: a comprehensive review." European journal of cancer 54 (2016):

[3] Crews, Jonathan, et al. "Ipilimumabassociated retinopathy." Ophthalmic Surgery, Lasers and Imaging Retina 46.6

[4] Bossart, Simon, et al. "Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma." The Oncologist

[5] Pillai, Rathi Narayana, et al. "Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC)." (2016):

[6] Hodi, F. Stephen, et al. "Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study." (2015):

[7] Larkin, James, et al. "Combined nivolumab and ipilimumab or

[8] Friedman, Claire F., Tracy A.

monotherapy in untreated melanoma." New England journal of medicine 373.1

Proverbs-Singh, and Michael A. Postow. "Treatment of the immune-related adverse effects of immune checkpoint

139-148.

**References**

(2015): 658-660.

22.6 (2017): 749.

9035-9035.

9004-9004.

(2015): 23-34.

*The Endocrinological Side Effects of Immunotherapies DOI: http://dx.doi.org/10.5772/intechopen.96491*
